Overview

Ablynx is a biopharmaceutical company focused on the discovery and development of Nanobodies^®, a novel class of antibody-derived therapeutic proteins based on single-domain antibody fragments, for a range of serious life-threatening human diseases.

The Company currently has seven Nanobodies^® in clinical development and more than 25 projects in its pipeline.

Upcoming events

KBC Securities Healthcare Conference
19 March 2012 – Brussels, Belgium

Kempen Life Sciences Conference
22 March 2012 – Amsterdam, The Netherlands

MidCap Event 2012
29-30 March 2012 – Euronext Brussels, Belgium

Past events & presentations

30th Annual J.P. Morgan Healthcare Conference - 9-12 January 2012
Berenberg Bank, Annual Conference - 2 December 2011
Pfizer successfully completes a Phase II study with ATN-103 – 17 May 2011